Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0564)
DME Name Matrix metalloproteinase-9 (MMP-9), Homo sapiens DME Info
UniProt ID
MMP9_HUMAN
EC Number    EC: 3.4.24.35     (Click to Show/Hide the Complete EC Tree)
Hydrolases
Peptidase
Metallopeptidase
EC: 3.4.24.35
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      ICD Disease Classification Healthy
               ICD-11: Healthy Click to Show/Hide the Full List of HOSPPI:      11 HOSPPI
                     Transcription-factor regulation
                            I-kappa-B-kinase beta (IKBKB) Health Repression
Uniprot ID
IKKB_HUMAN
Interaction Name IKBKB-MMP9 interaction [4]
Studied Cell Lines Human mesenchymal stem cell line
Description I-kappa-B-kinase beta (IKBKB) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between IKBKB and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Krueppel-like factor 6 (KLF6) Health Repression
Uniprot ID
KLF6_HUMAN
Interaction Name KLF6-MMP9 interaction [5], [6]
Studied Cell Lines Blood outgrowth endothelial cell line
Ensembl ID
ENSG00000067082
Description Krueppel-like factor 6 (KLF6) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF6 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            MHC II transactivator (CIITA) Health Repression
Uniprot ID
C2TA_HUMAN
Interaction Name CIITA-MMP9 interaction [7]
Studied Cell Lines STAT-1-deficient U3A cell line
Description MHC II transactivator (CIITA) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between CIITA and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Nuclear factor kappa-B p105 (NFKB1) Health Repression
Uniprot ID
NFKB1_HUMAN
Interaction Name NFKB1-MMP9 interaction [8], [9]
Studied Cell Lines Vascular smooth muscle cell line
Ensembl ID
ENSG00000109320
Description Nuclear factor kappa-B p105 (NFKB1) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between NFKB1 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            PPA receptor alpha (PPARA) Health Repression
Uniprot ID
PPARA_HUMAN
Interaction Name PPARA-MMP9 interaction [10]
Studied Cell Lines hCMEC/D3 cell line
Ensembl ID
ENSG00000186951
Description PPA receptor alpha (PPARA) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between PPARA and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Proto-oncogene c-Fos (FOS) Health Activation
Uniprot ID
FOS_HUMAN
Interaction Name FOS-MMP9 interaction [11], [12]
Studied Cell Lines H9c2 cell line
Ensembl ID
ENSG00000170345
Description Proto-oncogene c-Fos (FOS) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between FOS and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                            Transcription factor AP-1 (JUN) Health Repression
Uniprot ID
JUN_HUMAN
Interaction Name JUN-MMP9 interaction [13]
Studied Cell Lines Vascular smooth muscle cell line
Ensembl ID
ENSG00000177606
Description Transcription factor AP-1 (JUN) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between JUN and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Transcription factor Sp2 (SP2) Health Repression
Uniprot ID
SP2_HUMAN
Interaction Name SP2-MMP9 interaction [5]
Studied Cell Lines Blood outgrowth endothelial cell line
Ensembl ID
ENSG00000167182
Description Transcription factor Sp2 (SP2) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SP2 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                     Non-coding RNA regulation
                            hsa-let-7e-5p Health Suppression
miRBase ID
MIMAT0000066
Interaction Name hsa-let-7e-5p--MMP9 regulation [1]
Studied Cell Lines Adipose-derived stem cells
Description hsa-let-7e-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
                            hsa-miR-132-3p Health Suppression
miRBase ID
MIMAT0000426
Interaction Name hsa-miR-132-3p--MMP9 regulation [2]
Studied Cell Lines HEK293 cell line
Description hsa-miR-132-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
                            hsa-miR-29b-3p Health Suppression
miRBase ID
MIMAT0000100
Interaction Name hsa-miR-29b-3p--MMP9 regulation [3]
Studied Cell Lines HEK293 cell line
Description hsa-miR-29b-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
      ICD Disease Classification 02 Neoplasms
               ICD-11: 2A00 Brain cancer Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                     Non-coding RNA regulation
                            hsa-miR-15b-5p Glioblastoma Suppression
miRBase ID
MIMAT0000417
Interaction Name hsa-miR-15b-5p--MMP9 regulation [14]
Studied Cell Lines U87 cell line
Description hsa-miR-15b-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
                            hsa-miR-451a Glioblastoma Suppression
miRBase ID
MIMAT0001631
Interaction Name hsa-miR-451a--MMP9 regulation [15]
Studied Cell Lines A172, LN229 and U251 cell lines
Description hsa-miR-451a is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2A82 Chronic lymphocytic leukemia Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     Transcription-factor regulation
                            STAT 1-alpha/beta (STAT1) Chronic lymphocytic leukaemia Repression
Uniprot ID
STAT1_HUMAN
Interaction Name STAT1-MMP9 interaction [16]
Studied Cell Lines B-cell chronic lymphocytic leukemia cell line
Ensembl ID
ENSG00000115415
Description STAT 1-alpha/beta (STAT1) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between STAT1 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2B33 Acute lymphoblastic leukemia Click to Show/Hide the Full List of HOSPPI:        3 HOSPPI
                     Transcription-factor regulation
                            MAD homolog 3 (SMAD3) Acute lymphoblastic leukemia Repression
Uniprot ID
SMAD3_HUMAN
Interaction Name SMAD3-MMP9 interaction [17]
Studied Cell Lines Mono-Mac-6 and RAW264.7 monocyte/macrophage cell lines
Ensembl ID
ENSG00000166949
Description MAD homolog 3 (SMAD3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SMAD3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            SIR2-like protein 1 (SIRT1) Acute lymphoblastic leukemia Repression
Uniprot ID
SIR1_HUMAN
Interaction Name SIRT1-MMP9 interaction [13], [18]
Studied Cell Lines U937 cell line
Description SIR2-like protein 1 (SIRT1) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SIRT1 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Transcription factor p65 (RELA) Acute lymphoblastic leukemia Repression
Uniprot ID
TF65_HUMAN
Interaction Name RELA-MMP9 interaction [8], [9], [17]
Studied Cell Lines Mono-Mac-6 and RAW264.7 monocyte/macrophage cell lines
Ensembl ID
ENSG00000173039
Description Transcription factor p65 (RELA) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between RELA and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2B51 Osteosarcoma Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     Non-coding RNA regulation
                            hsa-miR-491-5p Osteosarcoma Suppression
miRBase ID
MIMAT0002807
Interaction Name hsa-miR-491-5p--MMP9 regulation [19]
Studied Cell Lines Osteosarcoma cells
Description hsa-miR-491-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2B5J Fibrosarcoma Click to Show/Hide the Full List of HOSPPI:        3 HOSPPI
                     Transcription-factor regulation
                            Transcription factor p65 (RELA) Fibrosarcoma Activation
Uniprot ID
TF65_HUMAN
Interaction Name RELA-MMP9 interaction [21], [22], [12]
Studied Cell Lines HT1080 cell line
Ensembl ID
ENSG00000173039
Description Transcription factor p65 (RELA) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between RELA and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                     Histone modification
                            Histone deacetylase 1 (HDAC1) Fibrosarcoma Repression
Uniprot ID
HDAC1_HUMAN
Interaction Name HDAC1-MMP9 interaction [20]
Studied Cell Lines HT1080 cell line
Description Histone deacetylase 1 (HDAC1) is reported to deacetylate the MMP9 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between HDAC1 and MMP9 can inhibit the drug-metabolizing process of Matrix metalloproteinase-9.
                            Histone deacetylase 1 (HDAC1) Fibrosarcoma Repression
Uniprot ID
HDAC1_HUMAN
Interaction Name HDAC1-MMP9 interaction [20]
Studied Cell Lines HT1080 cell line
Description Histone deacetylase 1 (HDAC1) is reported to deacetylate the MMP9 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between HDAC1 and MMP9 can inhibit the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2B60 Squamous cell carcinoma Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     Transcription-factor regulation
                            E74-like factor 3 (ELF3) Squamous cell carcinoma Repression
Uniprot ID
ELF3_HUMAN
Interaction Name ELF3-MMP9 interaction [23]
Studied Cell Lines HSC-3 and KB cell lines
Ensembl ID
ENSG00000163435
Description E74-like factor 3 (ELF3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ELF3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2B71 Gastric cancer Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                     Transcription-factor regulation
                            Runt transcription factor 3 (RUNX3) Gastric cancer Repression
Uniprot ID
RUNX3_HUMAN
Interaction Name RUNX3-MMP9 interaction [25]
Studied Cell Lines SGC7901 and MKN28 cell lines
Ensembl ID
ENSG00000020633
Description Runt transcription factor 3 (RUNX3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between RUNX3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                     Non-coding RNA regulation
                            hsa-miR-524-5p Gastric cancer Suppression
miRBase ID
MIMAT0002849
Interaction Name hsa-miR-524-5p--MMP9 regulation [24]
Studied Cell Lines SGC-7901 and MGC-803 cell lines
Description hsa-miR-524-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2B90 Colorectal cancer Click to Show/Hide the Full List of HOSPPI:        4 HOSPPI
                     Transcription-factor regulation
                            Krueppel-like factor 5 (KLF5) Colorectal cancer Activation
Uniprot ID
KLF5_HUMAN
Interaction Name KLF5-MMP9 interaction [27]
Studied Cell Lines Caco-2 cell line
Ensembl ID
ENSG00000102554
Description Krueppel-like factor 5 (KLF5) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF5 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                            TF factor AP-2-alpha (TFAP2A) Colorectal cancer Repression
Uniprot ID
AP2A_HUMAN
Interaction Name TFAP2A-MMP9 interaction [28]
Studied Cell Lines SW480 and KM12C cell lines
Ensembl ID
ENSG00000137203
Description TF factor AP-2-alpha (TFAP2A) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between TFAP2A and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Transcription factor Sp1 (SP1) Colorectal cancer Activation
Uniprot ID
SP1_HUMAN
Interaction Name SP1-MMP9 interaction [22], [29]
Studied Cell Lines CT26 cell line
Ensembl ID
ENSG00000185591
Description Transcription factor Sp1 (SP1) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SP1 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                     Non-coding RNA regulation
                            hsa-miR-302a-5p Colorectal cancer Suppression
miRBase ID
MIMAT0000683
Interaction Name hsa-miR-302a-5p--MMP9 regulation [26]
Studied Cell Lines SW480 cell line
Description hsa-miR-302a-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2C12 Liver cancer Click to Show/Hide the Full List of HOSPPI:        4 HOSPPI
                     Transcription-factor regulation
                            Krueppel-like factor 5 (KLF5) Liver cancer Activation
Uniprot ID
KLF5_HUMAN
Interaction Name KLF5-MMP9 interaction [27]
Studied Cell Lines HepG2, HuH7 and HLE cell lines
Ensembl ID
ENSG00000102554
Description Krueppel-like factor 5 (KLF5) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF5 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                     Non-coding RNA regulation
                            hsa-miR-133a-5p Liver cancer Suppression
miRBase ID
MIMAT0026478
Interaction Name hsa-miR-133a-5p--MMP9 regulation [30]
Studied Cell Lines HepG2 and SMMC-7721 cell lines
Description hsa-miR-133a-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
                            hsa-miR-143-3p Liver cancer Suppression
miRBase ID
MIMAT0000435
Interaction Name hsa-miR-143-3p--MMP9 regulation [31]
Studied Cell Lines HepG2 cell line
Description hsa-miR-143-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
                            hsa-miR-338-3p Liver cancer Suppression
miRBase ID
MIMAT0000763
Interaction Name hsa-miR-338-3p--MMP9 regulation [32]
Studied Cell Lines SK-HEP-1 and SMMC-7721 cell lines
Description hsa-miR-338-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2C25 Lung cancer Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                     Transcription-factor regulation
                            E74-like factor 4 (ELF4) Lung cancer Repression
Uniprot ID
ELF4_HUMAN
Interaction Name ELF4-MMP9 interaction [33]
Studied Cell Lines A549 cell line
Ensembl ID
ENSG00000102034
Description E74-like factor 4 (ELF4) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ELF4 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Protein C-ets-2 (ETS2) Lung cancer Activation
Uniprot ID
ETS2_HUMAN
Interaction Name ETS2-MMP9 interaction [33]
Studied Cell Lines A549 cell line
Ensembl ID
ENSG00000157557
Description Protein C-ets-2 (ETS2) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ETS2 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2C30 Melanoma Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     Non-coding RNA regulation
                            hsa-miR-204-5p Melanoma Suppression
miRBase ID
MIMAT0000265
Interaction Name hsa-miR-204-5p--MMP9 regulation [34]
Studied Cell Lines A375 cell line
Description hsa-miR-204-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2C60 Breast cancer Click to Show/Hide the Full List of HOSPPI:        4 HOSPPI
                     Transcription-factor regulation
                            His-acetyltransferase p300 (EP300) Breast cancer Activation
Uniprot ID
EP300_HUMAN
Interaction Name EP300-MMP9 interaction [35]
Studied Cell Lines MDA-MB-231 cell line
Description His-acetyltransferase p300 (EP300) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between EP300 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                            Krueppel-like factor 8 (KLF8) Breast cancer Activation
Uniprot ID
KLF8_HUMAN
Interaction Name KLF8-MMP9 interaction [36]
Studied Cell Lines MCF10A cell line
Ensembl ID
ENSG00000102349
Description Krueppel-like factor 8 (KLF8) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF8 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                            STAT 3 (STAT3) Breast cancer Repression
Uniprot ID
STAT3_HUMAN
Interaction Name STAT3-MMP9 interaction [37]
Studied Cell Lines MDA-MB-231 cell line
Ensembl ID
ENSG00000168610
Description STAT 3 (STAT3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between STAT3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Transcription factor AP-1 (JUN) Breast cancer Activation
Uniprot ID
JUN_HUMAN
Interaction Name JUN-MMP9 interaction [38], [11]
Studied Cell Lines MCF-7, MDA-MB-231, MDA-MB-468 and MDA-MB-435 cell lines
Ensembl ID
ENSG00000177606
Description Transcription factor AP-1 (JUN) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between JUN and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2C73 Ovarian cancer Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                     Transcription-factor regulation
                            Protein C-ets-1 (ETS1) Ovarian cancer Activation
Uniprot ID
ETS1_HUMAN
Interaction Name ETS1-MMP9 interaction [40]
Studied Cell Lines SKOV3 cell line
Ensembl ID
ENSG00000134954
Description Protein C-ets-1 (ETS1) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ETS1 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
                     Non-coding RNA regulation
                            hsa-miR-9-3p Ovarian cancer Suppression
miRBase ID
MIMAT0000442
Interaction Name hsa-miR-9-3p--MMP9 regulation [39]
Studied Cell Lines OVCAR-3 cell line
Description hsa-miR-9-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
               ICD-11: 2C82 Prostate cancer Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                     Transcription-factor regulation
                            Prostate-specific Ets (SPDEF) Prostate cancer Repression
Uniprot ID
SPDEF_HUMAN
Interaction Name SPDEF-MMP9 interaction [41], [42]
Studied Cell Lines PC3, LNCaP and C4-2B cell lines
Ensembl ID
ENSG00000124664
Description Prostate-specific Ets (SPDEF) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SPDEF and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
                            Zinc finger SNAI2 (SNAI2) Prostate cancer Activation
Uniprot ID
SNAI2_HUMAN
Interaction Name SNAI2-MMP9 interaction [43]
Studied Cell Lines PC3, DU145, 22RV1, and LNCaP cell lines
Ensembl ID
ENSG00000019549
Description Zinc finger SNAI2 (SNAI2) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SNAI2 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
               ICD-11: 2C90 Renal cell carcinoma Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                     Non-coding RNA regulation
                            hsa-miR-133b Renal cell carcinoma Suppression
miRBase ID
MIMAT0000770
Interaction Name hsa-miR-133b--MMP9 regulation [44]
Studied Cell Lines 786-O and A498 cell lines
Description hsa-miR-133b is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
                            hsa-miR-942-3p Renal cell carcinoma Suppression
miRBase ID
MIMAT0026734
Interaction Name hsa-miR-942-3p--MMP9 regulation [45]
Studied Cell Lines Metastatic renal cell carcinoma cells
Description hsa-miR-942-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
      ICD Disease Classification 11 Circulatory system diseases
               ICD-11: BA4Z Acute coronary syndrome Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     Transcription-factor regulation
                            PPA receptor gamma (PPARG) Acute coronary syndrome Repression
Uniprot ID
PPARG_HUMAN
Interaction Name PPARG-MMP9 interaction [46]
Studied Cell Lines Peripheral blood mononuclear cell line
Ensembl ID
ENSG00000132170
Description PPA receptor gamma (PPARG) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between PPARG and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
References
1 miRNA let-7e targeting MMP9 is involved in adipose-derived stem cell differentiation toward epithelia. Cell Death Dis. 2014 Feb 6;5(2):e1048.
2 miR-132 Regulates Dendritic Spine Structure by Direct Targeting of Matrix Metalloproteinase 9 mRNA. Mol Neurobiol. 2016 Sep;53(7):4701-12.
3 GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013 Feb;15(2):201-13.
4 IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med (Berl). 2008 Oct;86(10):1183-92.
5 Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem. 2006 Dec 22;281(51):39105-13.
6 The butanol fraction of guava (Psidium cattleianum Sabine) leaf extract suppresses MMP-2 and MMP-9 expression and activity through the suppression of the ERK1/2 MAPK signaling pathway. Nutr Cancer. 2012;64(2):255-66.
7 Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression. J Biol Chem. 2004 Sep 10;279(37):38577-89.
8 A novel function of benzyl isothiocyanate in vascular smooth muscle cells: the role of ERK1/2, cell cycle regulation, and matrix metalloproteinase-9. J Cell Physiol. 2005 Jun;203(3):493-500.
9 Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther. 2008 Jun;7(6):1604-14.
10 PPARalpha and PPARgama protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling. FASEB J. 2011 Nov;25(11):3979-88.
11 Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9. Biochem Biophys Res Commun. 2008 Nov 28;376(4):743-7.
12 Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sci. 2011 Mar 14;88(11-12):465-72.
13 SIRT1 acts as a modulator of neointima formation following vascular injury in mice. Circ Res. 2011 May 13;108(10):1180-9.
14 Mangiferin regulates proliferation and apoptosis in glioma cells by induction of microRNA-15b and inhibition of MMP-9 expression. Oncol Rep. 2015 Jun;33(6):2815-20.
15 MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010 Nov 4;1359:14-21.
16 VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood. 2010 Jan 28;115(4):846-9.
17 Suppression of matrix metalloproteinase-9 Transcription by transforming growth factor-beta Is mediated by a nuclear factor-kappaB site. Biochem J. 2004 Jul 15;381(Pt 2):413-22.
18 A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009 Sep;23(9):2810-9.
19 A Single Nucleotide Polymorphism (rs1056629) in 3'-UTR of MMP-9 is Responsible for a Decreased Risk of Metastatic Osteosarcoma by Compromising its Interaction with microRNA-491-5p. Cell Physiol Biochem. 2016;38(4):1415-24.
20 AP-1 mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon beta. PLoS One. 2012;7(8):e42152.
21 Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. Gynecol Oncol. 2009 Sep;114(3):509-15.
22 Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion in human MDA-MB-231 breast cancer cells. FEBS Lett. 2011 Oct 20;585(20):3328-36.
23 ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Oral Dis. 2008 Mar;14(2):144-9.
24 MicroRNA-524-5p suppresses the growth and invasive abilities of gastric cancer cells. Oncol Lett. 2016 Mar;11(3):1926-1932.
25 Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int J Cancer. 2011 Oct 1;129(7):1586-98.
26 Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways. Int J Clin Exp Pathol. 2015 May 1;8(5):4481-91.
27 Kruppel-like factor 5 causes cartilage degradation through transactivation of matrix metalloproteinase 9. J Biol Chem. 2008 Sep 5;283(36):24682-9.
28 Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene. 2007 Jun 14;26(28):4049-58.
29 A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chem Biol Interact. 2009 Oct 30;181(3):440-6.
30 MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep. 2015 May;11(5):3900-7.
31 miR-143 down-regulates TLR2 expression in hepatoma cells and inhibits hepatoma cell proliferation and invasion. Int J Clin Exp Pathol. 2015 Oct 1;8(10):12738-47.
32 miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol. 2011 Nov;225(3):463-72.
33 The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res. 2002 Nov 15;62(22):6579-86.
34 miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanoma. Onco Targets Ther. 2017 Feb 27;10:1237-1246.
35 LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med. 2008 Oct 31;40(5):514-22.
36 KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene. 2011 Apr 21;30(16):1901-11.
37 A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010 May 15;79(10):1398-409.
38 Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res. 2005 Apr 15;305(1):83-98.
39 miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1/CXCR4 pathway. Exp Ther Med. 2017 Apr;13(4):1203-1208.
40 ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem. 2012 Apr 27;287(18):15001-15.
41 Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer. 2010 Jun 15;9:148.
42 The transcription factor SPDEF suppresses prostate tumor metastasis. J Biol Chem. 2012 Aug 24;287(35):29968-78.
43 SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer. 2011 Nov 10;10:139.
44 microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep. 2014 Jun;9(6):2491-8.
45 Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014 Jan 24;9(1):e86263.
46 Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Aug;37(8):739-45.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.